PERNIX THERAPEUTICS HLDGS IN's ticker is PTX and the CUSIP is 71426V108. A total of 105 filers reported holding PERNIX THERAPEUTICS HLDGS IN in Q3 2015. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2016 | $14,000 | +55.6% | 21,619 | 0.0% | 0.00% | – |
| Q2 2016 | $9,000 | -98.6% | 21,619 | -96.4% | 0.00% | – |
| Q1 2016 | $625,000 | -60.5% | 594,274 | +11.0% | 0.00% | – |
| Q4 2015 | $1,582,000 | -6.7% | 535,201 | -0.4% | 0.00% | – |
| Q3 2015 | $1,695,000 | -37.5% | 537,179 | +17.2% | 0.00% | – |
| Q2 2015 | $2,712,000 | -43.0% | 458,250 | +3.0% | 0.00% | – |
| Q1 2015 | $4,754,000 | +25.6% | 444,799 | +10.4% | 0.00% | – |
| Q4 2014 | $3,784,000 | +84.9% | 402,738 | +51.1% | 0.00% | – |
| Q3 2014 | $2,047,000 | -8.8% | 266,533 | +6.5% | 0.00% | – |
| Q2 2014 | $2,245,000 | +112.8% | 250,217 | +26.9% | 0.00% | – |
| Q1 2014 | $1,055,000 | -32.1% | 197,104 | -39.3% | 0.00% | – |
| Q4 2013 | $1,553,000 | +228.3% | 324,654 | +86.9% | 0.00% | – |
| Q3 2013 | $473,000 | +22.9% | 173,673 | +62.8% | 0.00% | – |
| Q2 2013 | $385,000 | – | 106,696 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Stonepine Capital Management, LLC | 2,484,649 | $7,330,000 | 8.59% |
| Avoro Capital Advisors LLC | 5,144,916 | $15,178,000 | 5.23% |
| Broadfin Capital, LLC | 6,090,829 | $17,968,000 | 1.10% |
| Aisling Capital LLC | 2,010,000 | $5,930,000 | 1.02% |
| Healthcare Value Capital, LLC | 150,000 | $443,000 | 0.73% |
| ACUTA CAPITAL PARTNERS, LLC | 434,300 | $1,281,000 | 0.61% |
| WALL STREET ASSOCIATES | 696,300 | $2,054,000 | 0.58% |
| SEARLE & CO. | 172,500 | $500,000 | 0.48% |
| Elk Creek Partners, LLC | 2,253,667 | $6,648,000 | 0.47% |
| KOPP INVESTMENT ADVISORS LLC | 315,293 | $931,000 | 0.46% |